Anticancer agent icaritin induces apoptosis through caspase-dependent pathways in human hepatocellular carcinoma
Li Sun1, Qisong Peng2, Lili Qu1
1Department of Laboratory Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China.
Abstract:
Icaritin is an active ingredient derived from the plant Herba epimedium, which exhibits various pharmacological and biological activities. However, the function, and the underlying mechanisms of icaritin on the growth of SMMC‑7721 human hepatoma cells have yet to be elucidated. The present study aimed to investigate the function and underlying mechanisms of icaritin in the growth of SMMC‑7721 cells. The cells were treated with varying concentrations of icaritin for 12, 24 and 48 h, respectively, prior to cytotoxic analysis. Apoptosis of SMMC‑7721 cells following treatment with icaritin was measured using flow cytometry. The gene expression of mitochondria‑ and Fas‑mediated caspase‑dependent pathways was detected by reverse transcription‑quantitative polymerase chain reaction and western blotting. Statistical analysis was performed by Student's t‑test and one‑way analysis or variance. The present study demonstrated that treatment with icaritin significantly inhibited growth, and induced apoptosis of SMMC‑7721 cells, in a time‑ and dose‑dependent manner. In addition, icaritin triggered the mitochondrial/caspase apoptotic pathway, by decreasing the Bcl‑2/Bax protein ratio and increasing activation of caspase‑3. Icaritin also activated the Fas‑mediated apoptosis pathway, as was evident by the increased expression levels of Fas and activation of caspase‑8. These data suggest that icaritin may be a potent growth inhibitor and induce apoptosis of SMMC‑7721 cells through the mitochondria‑ and Fas‑mediated caspase‑dependent pathways. The present study may provide experimental evidence for preclinical and clinical evaluations of icaritin for HCC therapy.
Insights
Icaritin, derived from Herba epimedium, inhibits SMMC-7721 human hepatoma cell growth and induces apoptosis. It activates both mitochondrial/caspase and Fas-mediated pathways, showing potential for hepatocellular carcinoma (HCC) therapy.
Area of Science:
- Pharmacology
- Cell Biology
- Hepatocellular Carcinoma Research
Background:
- Icaritin, from Herba epimedium, has known biological activities.
- Mechanisms of icaritin's effect on SMMC-7721 human hepatoma cells are not fully understood.
Purpose of the Study:
- To investigate the function of icaritin on SMMC-7721 cell growth.
- To elucidate the underlying molecular mechanisms of icaritin's action.
Main Methods:
- SMMC-7721 cells treated with varying icaritin concentrations.
- Cytotoxicity, apoptosis (flow cytometry), gene expression (RT-qPCR), and protein levels (Western blotting) analyzed.
- Mitochondrial and Fas-mediated caspase pathways investigated.
Main Results:
- Icaritin significantly inhibited SMMC-7721 cell growth in a time- and dose-dependent manner.
- Icaritin induced apoptosis by activating the mitochondrial/caspase pathway (decreased Bcl-2/Bax ratio, increased caspase-3 activation).
- Icaritin activated the Fas-mediated apoptosis pathway (increased Fas and caspase-8 activation).
Conclusions:
- Icaritin inhibits SMMC-7721 cell growth and induces apoptosis via mitochondrial and Fas-mediated caspase pathways.
- Icaritin demonstrates potential as a therapeutic agent for hepatocellular carcinoma (HCC).
- Provides evidence for preclinical and clinical evaluation of icaritin in HCC therapy.
More Related Videos
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Caspases
Cellular Injury V: Apoptosis and Autophagy
Apoptosis
Mutagenicity and Carcinogenicity


